NASDAQ$BCAB
Bioatla Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
BioAtla reported financial results for Q4 2022 and highlighted recent progress.
BioAtla reported a net loss of $27.5 million for the quarter ended December 31, 2022, compared to a net loss of $23.4 million for the same quarter in 2021. Cash and cash equivalents were $215.5 million as of December 31, 2022.
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23
- Initiated the potentially registrational Phase 2, part 2 BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) study in 1H23 including more frequent, dose-intensive regimens
- Achieved First Patient In (FPI) for CAB-ROR2 BA3021 Phase 2 squamous cell carcinoma of the head & neck (SCCHN) study
- Cleared DLT observation period for CAB-CTLA-4 (BA3071) 210mg (3mg/kg) Q3W in combination with nivolumab 3mg/kg Q3W; Phase 1 dose-escalation ongoing with data readout and initiation of Phase 2 both anticipated in 2H23
Headline financials
Revenue & EPS history
Bioatla · Revenue · Quarterly
$0
Forward guidance
BioAtla anticipates several important milestones and value inflection points to be achieved and communicated throughout 2023.
Tailwinds
- Advancement of Phase 2, part 2 potentially registrational BA3011 trial in NSCLC
- Completion of Phase 2 study for BA3021 in NSCLC enabling FDA discussions regarding a potential registrational trial
- Initiation of a phase 2 trial for BA3071
- Potential additional IND submissions for pre-clinical CAB bispecific and next generation ADC candidates in 2023 through 2024
- Cash balance of $215.5 million at year-end 2022 expected to provide funding into 2025
Headwinds
- Potential delays in clinical and pre-clinical trials due to the global COVID-19 pandemic
- Other potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy
- Uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data
- Whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies
- Dependence on the success of our CAB technology platform
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+5.5%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+7.5%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+76.7%
Q2 2022
Best reaction
-37.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.4% | -18.1% | -15.1% | |
| Q3 2025 | +23.2% | +75.8% | +24.8% | |
| Q2 2025 | -5.6% | +3.2% | +41.3% | |
| Q1 2025 | -7.2% | -9.1% | +1.5% | |
| Q4 2024 | -4.9% | -13.5% | +12.2% | |
| Q3 2024 | +1.9% | +6.3% | -20.4% | |
| Q2 2024 | +5.8% | +0.7% | +25.2% | |
| Q1 2024 | +13.6% | +7.2% | -40.5% | |
| Q4 2023 | +48.5% | +47.6% | -3.4% | |
| Q3 2023 | -10.3% | -24.2% | -15.8% | |
| Q2 2023 | -0.3% | -8.4% | -16.1% | |
| Q1 2023 | +10.9% | +7.9% | +10.3% | |
| Q4 2022 | +0.9% | +0.4% | +48.3% | |
| Q3 2022 | +17.1% | +22.8% | +63.1% | |
| Q2 2022 | +76.7% | +86.9% | +142.2% | |
| Q1 2022 | -37.3% | -43.9% | -28.2% | |
| Q4 2021 | +1.9% | -15.1% | -22.8% | |
| Q3 2021 | -0.3% | -1.9% | -24.5% | |
| Q2 2021 | -4.4% | -2.7% | -9.4% | |
| Q1 2021 | -2.4% | -1.9% | +6.6% | |
| Q4 2020 | -10.6% | -21.5% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro